Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure  by van Kimmenade, Roland R. et al.
U
N
f
R
P
A
C
M
I
d
3
(
r
i
r
s
t
t
a
n
N
c
M
l
M
r
D
D
a
Journal of the American College of Cardiology Vol. 48, No. 6, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
PHeart Failure
tility of Amino-Terminal Pro-Brain
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or the Evaluation of Patients With Acute Heart Failure
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aastricht, the Netherlands; and Boston, Massachusetts
OBJECTIVES This study sought to explore the role of new biomarkers in heart failure (HF).
BACKGROUND We investigated the utility of novel serum markers alone or together with natriuretic peptide
testing for diagnosis and short-term prognosis estimation in subjects with acute HF.
METHODS Plasma levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP), apelin, and
galectin-3 were measured in 599 patients presenting with dyspnea at the emergency
department, of which 209 (35%) had acute HF.
RESULTS The NT-proBNP was superior to either apelin or galectin-3 for diagnosis of acute HF,
although galectin-3 levels were significantly higher in subjects with HF compared with those
without. Receiver operating characteristic analysis for mortality prediction showed that, for
60-day prognosis, galectin-3 had the greatest area under the curve (AUC) at 0.74 (p 
0.0001), whereas NT-proBNP and apelin had an AUC of 0.67 (p  0.009) and 0.54 (p 
0.33). In a multivariate logistic regression analysis, an elevated level of galectin-3 was the best
independent predictor of 60-day mortality (odds ratio 10.3, p  0.01) or the combination of
death/recurrent HF within 60 days (odds ratio 14.3, p  0.001). The Kaplan-Meier analyses
showed that the combination of an elevated galectin-3 with NT-proBNP was a better
predictor of mortality than either of the 2 markers alone.
CONCLUSIONS Our data show potential utility of galectin-3 as a useful marker for evaluation of patients with
suspected or proven acute HF, whereas apelin measurement was not useful for these
indications. Moreover, the combination of galectin-3 with NT-proBNP was the best
predictor for prognosis in subjects with acute HF. (J Am Coll Cardiol 2006;48:1217–24)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.061© 2006 by the American College of Cardiology Foundation
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pt is estimated that the probability for an adult individual to
evelop heart failure (HF) during their lifetime is 20% to
0% (1,2), with attendant financial costs for modern society
3). Additionally, despite the introduction of therapies to
educe mortality, the 30-day cumulative survival rate after
ncident HF exacerbation is only 86% (1), leaving much
oom for improvement in the optimal evaluation and risk
tratification for those so afflicted (3–5).
To improve the short-term and long-term prognosis of
hose with HF, it would be important not only to improve
he identification of those with advanced HF, but to also be
ble to recognize those at highest risk for hazard. Unfortu-
ately, even for experienced physicians, it is a complex task
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ccepted March 28, 2006.o properly diagnose HF and accurately assess prognosis.
ccordingly, objective assessment using cardiac biomarkers
ay be one avenue in which patients may be routinely
valuated for the presence and severity of HF. To optimize
uch a strategy, the multiple mechanisms by which HF leads
o higher morbidity and mortality must be addressed. Thus,
single biomarker is not likely to be sufficient for a
omprehensive evaluation; a multimarker approach is there-
ore more likely to be of use (6).
Brain natriuretic peptide (BNP) and its cleavage equiva-
ent amino-terminal proBNP (NT-proBNP) are established
erum markers for diagnosis and prognosis in acute or
hronic HF (7–10). Both peptides derive from the cleavage
f proBNP, which production is rapidly upregulated when
ardiomyocytes are stretched (11). These peptides identify
ncreased wall stress, and have proven utility for confirming
he diagnosis of acute HF in breathless subjects and predict
dverse outcomes in these patients (7,8).
Aside from myocardial stretch, other mechanisms, such
s inflammation (12) or pathways regulating cardiac con-
ractility, might also play a role in HF, whereas these
rocesses might not be reflected by natriuretic peptideevels. Previous data suggest that activated cardiac macro-
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Utility of New Serum Markers in HF September 19 2006:1217–24hages produce galectin-3 (gal-3), a substance that impairs
ardiac function (13). In addition, concentrations of apelin,
potent endogenous inotropic peptide, have also been
uggested to identify the presence of HF and to parallel risk
or death (14). Despite promise of both gal-3 and apelin for
he evaluation of HF, little is known about the clinical
tility of either marker. Accordingly, in an effort to better
nderstand the individual and integrative role of these novel
arkers of HF, we tested the individual and combined
iagnostic and prognostic utilities of gal-3 or apelin, to-
ether with NT-proBNP, for the evaluation of subjects with
uspected or proven HF.
ETHODS
atients. The institutional review board approved all in-
estigational procedures involved in this study. The details
f the PRIDE (Pro-BNP Investigation of Dyspnea in the
mergency Department) study have been published previ-
usly (8). Briefly, this study examined 599 acutely dyspneic
ubjects presenting to the Emergency Department of the
assachusetts General Hospital, Boston. For each subject,
study physician assigned a final diagnosis of acute HF
from any cause) versus noncardiac dyspnea, using all
ospital records pertaining to the subject, starting from the
ime of emergency department presentation through 60-day
ollow-up. These records included (when available) office
otes, hospital discharge records, and results of all labora-
ory and imaging tests except for NT-proBNP levels. In
ddition, at 60 days an attempt was made to contact every
atient and review subsequent medical course after
resentation.
aboratory measurements. At the time of presentation, a
lood sample was collected into tubes containing ethylene
iaminetetraacetic acid; the blood was immediately pro-
essed and frozen at 80°C for later measurement of
T-proBNP, gal-3, and apelin.
The NT-proBNP analysis was performed with a com-
ercially available immunoassay (Elecsys proBNP, Roche
iagnostics, Indianapolis, Indiana) on an Elecsys 1010
Abbreviations and Acronyms
AUC  area under the curve
BNP  brain natriuretic peptide
CAD  coronary artery disease
CI  confidence interval
gal  galectin
HF  heart failure
IQR  interquartile range
NT-proBNP  amino-terminal pro-brain natriuretic
peptide
NYHA  New York Heart Association
OR  odds ratio
PRIDE  N-Terminal Pro-BNP Investigation of
Dyspnea in the Emergency Department
ROC  receiver-operating characteristicnalyzer according to established methods. pThe gal-3 was analyzed using a commercially available
nzyme-linked immunosorbent assay kit (Bender Medsystems,
ienna, Austria) and was measured on a Victor 2 plate reader
Perkin Elmer, Turku, Finland). Calibration of the assay was
ccording to the manufacturer’s protocol. Values were normal-
zed to a standard curve. The intra-assay and interassay
ariances for gal-3 were 5.6% and 8.6%, respectively.
Plasma apelin levels were determined using a commercially
vailable enzyme immunoassay without extraction (Phoenix
harmaceuticals, Belmont, California) according to the man-
facturer’s instructions. This assay employs an immunoaffinity
urified rabbit antibody specific for apelin 1-12. All apelin
ssays were performed in duplicate with intraexperimental
tandards using a Victor 3 plate reader (Perkin-Elmer, Welle-
ley, Massachusetts). Values were normalized to a standard
urve. The intra-assay and interassay variances for apelin were
9% and 17%, respectively. This assay uses an immunoaffinity
urified rabbit antibody specific for apelin 1-12. The antibody
as 100% cross-reactivity to apelin 1-12, 1-13, and 1-36; there
s no cross reactivity to adrenomedullin-52, BNP-32, CNP-22,
NP (25-56), ghrelin, endothelin-1, or bradykinin.
tatistical analyses. Medians of each marker in those with
nd without acute HF were compared using nonparametric
esting, whereas comparisons of biomarker concentrations
etween groups categorized by the New York Heart Asso-
iation (NYHA) functional classification were performed
sing Kruskal-Wallis testing. Otherwise, concentrations of
T-proBNP, gal-3, and apelin were log-transformed to
chieve normality, especially for the multivariate analyses.
omparisons of clinical characteristics between those sur-
iving to 60 days from presentation versus those who died
ere performed using chi-square tests for categorical data
nd the Wilcoxon rank-sum test for continuous data.
Receiver-operating characteristic (ROC) curves were uti-
ized to evaluate the utility of gal-3 and apelin compared to
T-proBNP for the diagnosis of acute HF in breathless
ubjects, as well as for identifying risk of death by 60 days in
hose with a diagnosis of acute HF. For those markers with a
ignificant area under the ROC curves, optimal cut-points for
dentifying or excluding risk of 60-day mortality in those with
cute HF were identified. ROC analyses were performed using
nalyse-It software (Analyse-It, Ltd, Leeds, United King-
om).
After the identification of optimal cut points for identifying
isk of mortality, Kaplan-Meier survival curves were con-
tructed to compare 60-day mortality rates in groups divided as
function of cardiac marker categories (neither above the
rognostic threshold, NT-proBNP alone above prognostic
hreshold, or both above the prognostic threshold) using the
og-rank test to compare the rates of mortality.
ultivariate analyses. Variables considered for univariate
nalyses are listed in Tables 1 and 2, as well as several not
isted, namely race, duration of symptoms, prior medication
se (including beta blocker, angiotensin-converting enzyme
nhibitor, and so on), body mass index, other laboratories at
resentation, as well as hospital course for index hospital-
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September 19 2006:1217–24 Utility of New Serum Markers in HFzation, including index diagnosis, and laboratory testing
including NT-proBNP and gal-3 results). Multivariable
tepwise logistic regression was used to identify independent
linical and biochemical predictors of death or death/
eadmission by 60 days in all subjects; 39 variables were
onsidered before univariate analysis, and only those with
Table 1. Comparison of Demographic Charact
Failure Patients
Characteristic
Age, yrs (mean  SD)
Male gender
Past medical history
Cardiomyopathy
Arrhythmia
Hypertension
Diabetes mellitus
Coronary artery disease
Myocardial infarction
Congestive heart failure
Obstructive lung disease
Pulse rate, beats/minute (mean  SD)
Glomerular filtration rate, ml/min/1.73 m2
Creatinine, mg/dl
Troponin T 0.03 ng/ml
Gal-3, ng/ml (median, IQR)
Apelin, pg/ml (median, IQR)
Gal  galectin; HF  heart failure; IQR  interquartile ra
able 2. Comparison of Characteristics Between Patients Dying
Characteristic
ge, yrs (mean  SD)
ale gender
ew York Heart Association functional class IV
ast medical history
Cardiomyopathy
Atrial arrhythmia
Hypertension
Diabetes mellitus
Coronary artery disease
Myocardial infarction
Congestive heart failure
edications at presentation
Beta-blocker
Loop diuretic
Digoxin
Angiotensin-converting enzyme inhibitor
Angiotensin receptor blocker
Nitrate
ulse rate, beats/minute (mean  SD)
ystolic blood pressure, mm Hg (mean  SD)
ody mass index, kg/m2 (mean  SD)
lomerular filtration rate, ml/min/1.73 m2 (mean  SD)
reatinine, mg/dl (mean  SD)
eft ventricular ejection fraction, % (mean  SD)
roponin T, ng/ml (median)
T-proBNP, pg/ml (median, IQR) 9
al-3, ng/ml (median, IQR)
pelin, pg/ml (median, IQR)T-proBNP  amino-terminal pro-brain natriuretic peptide; other abbreviations as in Taetention parameters 0.05 were considered for multivari-
te analyses. These are listed in Table 3.
In each analysis, goodness of fit was verified using the
osmer-Lemeshow test. For each independent predictor
n multivariable analyses, odds ratios (OR) were calcu-
ated with 95% confidence intervals (CI). For all statis-
ics of Heart Failure and Non-Heart
te HF
209)
No Acute HF
(n  390) p Value
 13.6 56.9  16.3 0.001
1% 51% 0.70
0% 6% 0.001
2% 9% 0.001
4% 41% 0.001
2% 18% 0.001
2% 20% 0.001
1% 9% 0.004
4% 9% 0.001
5% 42% 0.001
 23.5 88.2  22.3 0.85
 25.3 82.6  29.2 0.001
 0.48 0.98  0.33 0.005
6% 5% 0.001
.4–12.1) 6.9 (5.2–8.7) 0.001
77–480) 360 (290–495) 0.86
ng the 60 Days of Follow-Up With Those Surviving
ortality
n  17)
No Mortality
(n  192) p Value
80  8.3 72  13.7 0.06
53% 51% 0.41
53% 54% 0.74
29% 19% 0.20
41% 31% 0.55
59% 64% 0.74
22% 3.4% 0.002
47% 42% 0.79
24% 20% 0.71
65% 53% 0.51
53% 56% 0.98
59% 55% 0.78
29% 22% 0.88
18% 34% 0.14
12% 7% 0.20
15% 13% 0.45
92  19 86  24 0.09
23  29 141  30 0.39
26  4.9 27  7.0 0.88
.3  18.5 67.4  26.0 0.001
.4  0.52 1.1  0.48 0.001
.5  20 46.3  18 0.88
0.03 0.01 0.009
(3,864–15,717) 3,511 (1,610–9,541) 0.02
9.3–16.5) 9.0 (7.3–11.6) 0.001
250–576) 361 (277–478) 0.66erist
Acu
(n 
72.8
5
2
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Utility of New Serum Markers in HF September 19 2006:1217–24ical analyses, all p values are 2-sided, with results 0.05
onsidered.
ESULTS
iagnosis of HF in breathless subjects. As documented
reviously, of the 599 subjects in the PRIDE study, 209
35%) had acute HF as a final diagnosis. In these 209
atients, 135 patients had ischemic HF as cause of their HF,
hereas in 74 patients, there was a nonischemic or unknown
rigin. Among the 390 subjects without acute HF, 150 had
bstructive airways disease exacerbation, 64 had pneumonia,
1 had acute coronary syndromes, 19 had pulmonary em-
olism, and in 116 subjects dyspnea was attributed in 10
ases each to allergic reactions, anxiety, ascites, atrial fibril-
ation, fever, fibrothorax, gram-negative sepsis, herpes zos-
er, hypertension, lung carcinoma, pericarditis, supraven-
ricular tachycardia, or unknown.
As previously described for this population, median
oncentrations of NT-proBNP were higher in those with
cute HF versus those without (4,054 vs. 131 pg/ml, p 
.001) (8) (Table 1). Similarly, median concentrations of
al-3 were significantly higher in subjects with acute HF
9.2 pg/ml vs. 6.9 pg/ml, p  0.001). Median concentra-
ions of apelin were not different between those with and
ithout acute HF (357 pg/ml vs. 360 pg/ml, p  0.86).
With respect to HF etiology or type, there were no
ignificant differences in median concentrations of each
arker when considering ischemic versus nonischemic/
nknown origin of HF (NT-proBNP: 4,549 pg/ml vs.
,332 pg/ml, p  0.61; gal-3: 9.41 ng/ml vs. 8.80 ng/ml,
 0.35; apelin  357.0 pg/ml vs. 361.5 pg/ml; p  0.61).
n contrast, considering type of HF, median concentrations
f NT-proBNP were higher in patients with systolic HF
ersus those with nonsystolic HF (6,196 pg/ml vs. 3,134
g/ml, p  0.001). This pattern was not seen when
onsidering gal-3 (9.42 ng/ml vs. 8.96 ng/ml, p  0.97) or
pelin (351 pg/ml vs 362 pg/ml, p  0.66).
As previously described (8), ROC analysis examining
Table 3. Adjusted Multivariate Analysis for D
of Death/Recurrent Heart Failure Within 60 D
Predictor
Death within 60 days
Log galectin-3
Log NT-proBNP
Age
Glomerular filtration rate
NYHA functional classification
Composite of death/recurrent HF within 60 days
Log galectin-3
Log NT-proBNP
Age
Glomerular filtration rate
NYHA functional classification
NYHA  New York Heart Association; other abbreviationT-proBNP for diagnosis of acute HF yielded an area
s
onder the curve (AUC) for NT-proBNP of 0.94 (p 
.0001). The ROC analysis for gal-3 for the diagnosis of
F showed an AUC of 0.72 (p  0.0001), with an optimal
utoff of 6.88 ng/ml yielding a sensitivity of 80% and a
pecificity of 52%. In contrast, the AUC for apelin for
iagnosis of acute HF was 0.52 (p  0.23). A comparison
f the 3 ROC curves is showed in Figure 1. The NT-
roBNP had significantly greater AUC than either gal-3 or
pelin for the diagnosis of acute HF (p 0.0001); gal-3 had
ignificantly greater AUC than apelin (p  0.001). Neither
al-3 nor apelin concentrations correlated with NYHA
unctional classification.
When considering other important diagnoses in patients
ithout acute HF, we found no significant differences in
ither gal-3 or apelin concentrations in subjects with exac-
rbation of obstructive airway disease (median gal-3 con-
entration 7.38 ng/ml in patients with obstructive airway
Within 60 Days and for the Composite
dds Ratio
95% Confidence
Interval p Value
10.3 1.6–174.1 0.007
2.11 0.63–7.1 0.22
1.05 1.00–1.10 0.08
1.0 0.97–1.03 0.86
1.5 0.67–3.57 0.31
14.3 5.6–45.1 0.001
2.92 0.53–9.11 0.42
1.10 1.01–1.15 0.01
0.98 0.96–0.99 0.05
1.56 0.78–3.97 0.20
Table 2.
igure 1. Combined receiver-operating characteristic (ROC) curves for
mino-terminal pro-brain natriuretic peptide (NT-proBNP), galectin
gal)-3 and apelin for the diagnosis of heart failure in dyspneic patients.
he ROC analysis for NT-proBNP showed an area under the curve
AUC) for NT-proBNP of 0.94 (p 0.0001). The ROC analysis for gal-3eath
ays
Ohowed an AUC of 0.72 (p  0.0001). The AUC for apelin for diagnosis
f acute heart failure was 0.52 (p  0.23).
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September 19 2006:1217–24 Utility of New Serum Markers in HFisease vs. 8.15 ng/ml in the patients without obstructive
irway disease, p  0.08; median apelin concentrations 359
g/ml vs. 360 pg/ml, p  0.67 respectively) or pulmonary
hromboembolism (median gal-3 concentration 7.37 ng/ml
n patients with pulmonary thromboembolism vs. 7.51
g/ml in the patients without pulmonary thromboembo-
ism, p  0.88; median apelin concentrations 356 pg/ml vs.
60 pg/ml respectively, p  0.45) as a cause of their
yspnea.
al-3 and apelin concentrations and short-term progno-
is in HF. Among the 209 subjects with acute HF, 60
29%) had recurrent HF within 60 days, whereas 17 patients
8%) died by 60 days of follow-up. Demographic charac-
eristics expressed as a function of 60-day survival are shown
n Table 2. Median concentrations of gal-3 were signifi-
antly higher among those subjects dying by 60 days of
ollow-up (12.9 ng/ml, interquartile range [IQR]  9.3 to
6.5 ng/ml) than in those surviving (9.0 ng/ml, IQR  7.3
o 11.6, p  0.001) (Fig. 2). In contrast, median apelin
evels were not significantly different in decedents (339
g/ml, IQR  250 to 576 pg/ml) versus those surviving
361 pg/ml, IQR  277 to 478 pg/ml; p  0.66).
The ROC analysis for 60-day prognosis in acute HF
howed an AUC for gal-3 of 0.74 (p 0.0001), an AUC for
T-proBNP of 0.67 (p 0.009), and an AUC for apelin of
.54 (p  0.33), as depicted in Figure 3. In contrast to
iagnosis of acute HF, gal-3 showed a significantly greater
UC than either NT-proBNP (p  0.05) or apelin (p 
.0001). The optimal cut point for gal-3 for prediction of
0-day mortality was 9.42, which was 75% sensitive and
6% specific.
In adjusted multivariate analysis, log-transformed gal-3
erum levels were the best predictor of short-term mortality
OR 10.3, 95% CI 1.6 to 174.1, p 0.01; Table 3), superior
o NT-proBNP for this purpose. However, considering the
igure 2. Median galectin-3 levels among heart failure patients who diedc
n  17) within 60 days and those who survived (n  192). Boxes 
nterquartile ranges; whiskers  5th and 95th percentiles.ombination of NT-proBNP and gal-3 for identifying those
t highest risk for short-term mortality, Kaplan-Meier
nalyses showed that rates of death were highest in subjects
ith the combination of a gal-3 in excess of 9.42 ng/ml
ombined with NT-proBNP above 5,562 pg/ml (Fig. 4A).
A second adjusted multivariate analyses was performed,
xamining the combined end point of death or recurrent
F, and also showed that the log-transformed gal-3 serum
evels were the best predictor of events (OR 14.3, 95% CI
.6 to 45.1, p  0.001) (Table 3). Notably, the rates of
eath/recurrent HF were highest in subjects with elevations
f both NT-proBNP and gal-3 (Fig. 4B), with event rates
omewhat differently affected by respective markers: ele-
ated NT-proBNP concentrations paralleled higher rates of
eath (rather than recurrent HF), whereas gal-3 paralleled
levated rates for both death or recurrent HF.
ISCUSSION
e have shown that serum gal-3 levels are elevated in
ubjects with acute HF, and are prognostic of adverse
utcomes over a 60-day period after presentation. In con-
rast, another novel marker with suggested utility in HF
valuation, apelin, did not seem to have similar utility for
ither diagnosis or short-term prognosis in our study.
otably, gal-3 was able to identify those HF patients at risk
or short-term death or the combination of death or
eadmission within 60 days better than NT-proBNP; how-
ver, the combination of both markers seemed to further
efine predictive utility. This finding may be of clinical
mportance because the list of possible mortality-reducing
nterventions in HF continues to grow (15–18), although
isk stratification of HF populations continues to be imper-
ect. This leads to considerable burden for patients, health
igure 3. Combined receiver operating characteristic (ROC) curves for
mino-terminal pro-brain natriuretic peptide (NT-proBNP), galectin
gal)-3 and apelin for 60-day mortality in heart failure. The ROC analysis
howed an area under the curve (AUC) for gal-3 of 0.74 (p  0.0001), an
UC for NT-proBNP of 0.67 (p 0.009), and an AUC for apelin of 0.54
p  0.33).are workers, and health care policy makers. Therefore,
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Utility of New Serum Markers in HF September 19 2006:1217–24mproving prognostication of HF patients by combined
ssessment of serum markers may help to tailor the most
ppropriate treatment strategy on a more individualized basis.
To date, various approaches have been proposed to
rognosticate HF patients; recently the potential role of
erum markers for this role has drawn considerable interest
6). Although in our study NT-proBNP was superior to
al-3 for diagnosing acute HF, gal-3 was the stronger
redictor of short-term mortality. Interestingly, combining
al-3 measurement with NT-proBNP allowed identifica-
ion of a high-risk subgroup of acute HF subjects with a
onsiderably higher risk of mortality compared with those
ith low concentrations of both NT-proBNP and gal-3. In
igure 4. Kaplan-Meier analyses show that in patients with acute heart
ailure, at presentation the combination of a galectin-3 in excess of 9.42
g/ml combined with amino-terminal pro-brain natriuretic peptide (NT-
roBNP) above the optimal cut point (5,562 pg/ml) was associated with
igher rates of death (A) or mortality/recurrent heart failure (B) than either
f the 2 markers alone.ontrast to the findings with gal-3, in this study we could tot confirm a role for apelin (14) because it was neither able
o diagnose acute HF, nor to add prognostic information.
Because cardiomyocytes represent only one-third of the
yocardium, it is not surprising that cells other than
yocytes are also involved in the progression of acute HF
19). It is also well known that in the failing human heart,
mmunologic and inflammatory processes play an important
ole. Proinflammatory cytokines modulating several cardio-
ascular mechanisms and activated monocytes and macro-
hages are all involved in the pathogenesis of not only
schemic, but all forms of HF (12,20–22). We have previ-
usly shown that cardiac macrophages are activated at an
arly stage in failure-prone, hypertrophied hearts and that
hese macrophages express gal-3 (13). Intrapericardial infu-
ion of gal-3 led to both cardiac structural changes and
unctional impairment in rats (13). Here we translate these
xperimental findings to a clinical application. Measure-
ent of gal-3 is readily feasible and reliable in stored
lasma, and we here show that gal-3 levels are elevated in a
iscriminatory fashion in those with acute HF, with useful
nformation regarding both diagnosis and prognosis.
The gal-3 is a 26-kDa protein and a member of the
alectin family, a group of carbohydrate-binding proteins
ith a specific amino-acid sequence able to recognize
eta-galactose (23). Within this family, gal-3 is unique in
tructure; rather than consisting of merely one or two
arbohydrate-recognition domains, gal-3 consists of tandem
epeats of short amino-acid stretches fused onto the
arbohydrate-recognition domain (23–25). Secondly, al-
hough galectins lack a signal sequence necessary for secre-
ion, after macrophage activation, cytosolic gal-3 shifts to
he plasma membrane and integrates in vesicles extruding
rom the plasma membrane (26). Therefore, although gal-3
s expressed in cancerous tissue, cancer-associated stromal
ells, and even atherosclerotic lesions (23,27), it is not
ommonly significantly elevated in serum, other than in
elatively rare clinical situations, such as in widely metastatic
denocarcinoma (28). Although theoretically this may limit
he utility of gal-3 as a marker in HF, the differentiation
etween disseminated cancer and HF is usually easily done
y history and physical examination.
The identification of biologically unique biomarkers of-
ering complementary information for diagnosis (NT-
roBNP), and prognosis (gal-3), as well as additive prog-
ostic information when considered together, raises the
ossibility that our findings might be considered a step
urther toward a multimarker strategy for the evaluation of
ubjects with suspected or proven HF. Lee et al. (6) have
lready proposed a possible multimarker strategy and clas-
ified serum biomarkers in HF into four categories: neuro-
ormonal markers, markers of myocyte injury, markers of
atrix remodeling, and inflammation-related markers. In
ur analysis, we measured neurohormonal (NT-proBNP,
pelin) and inflammatory markers (gal-3), showing the
alue of combining the two classes to improve prognostica-
ion. Interestingly, a marker of myocyte necrosis (cTnT) did
n
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espite previous reports about the added value of combining
TnT with (NT-pro)BNP in HF (29–32). This may merely
eflect the limited power of our study.
Several other inflammation-related novel biomarkers
ave been previously investigated in smaller numbers of HF
atients, including tumor necrosis factor-alpha receptor 1,
-C chemokines, soluble ST-2 receptor, and apelin (33–
5). Although the exact role of apelin is still not completely
lucidated, it is considered to be a potent endogenous
notrope, involved in neurohumoral pathways (36,37). Be-
ause the expression pattern of apelin and the APJ receptor
s similar to expression pattern of angiotensinogen and the
T I receptor, combined with the fact that APJ-deficient
ice show an increased vasopressor response to angiotensin
I, this strongly suggests that apelin plays an important role
n the counter-regulation of the effects of angiotensin II
14,38,39). Previous reports suggest apelin as a candidate
arker in HF (14), although the relationship between
pelin and HF remains poorly understood. Although Foldes
t al. (40) showed that circulating levels of apelin indeed are
levated in the early stages of HF, such levels actually
ecreased in more advanced stages of HF. Our findings may
epresent a dynamic intermediate situation between these
wo steady states.
Limitations of our study include the fact that gal-3 did
ot correlate with severity of dyspnea as categorized by the
YHA functional classification. Such a lack of correlation
akes, according to some investigators, a new diagnostic
erum marker less suitable for clinical practice (41). How-
ver, we did not intend to investigate a new diagnostic
arker, because it is already known that NT-proBNP is an
xcellent diagnostic marker in this population (8). A prog-
ostic marker in HF actually does not necessarily correlate with
YHA functional classification, which is according to some
nvestigators rather subjective (42) and merely a “crude estima-
ion of a patient’s functional capacity” (43). In addition, the
elatively small number of subjects in our analysis, with
elatively limited numbers of adverse events, may be a limita-
ion as well. In addition, we were limited in the ability to
dequately explore the additional utility of a third marker with
otential prognostic value in HF such as cTnT (29–32).
In conclusion, in contrast to negative findings with
pelin, we found that gal-3 may be a novel marker for the
iagnosis and prognosis of acute HF. Combining clinical
easurement of gal-3 and NT-proBNP may be a paradigm
or the steps further toward a multimarker approach for
iagnosis, prognosis, and potentially optimal, more focused
herapeutic management of HF.
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